Key result
Inhibiting macropinocytosis substantially reduces macrophage LDL uptake and atherosclerotic lesions in hypercholesterolemic mice.
Answers are grounded in this paper and cite their sources.
Demonstrates that receptor-independent macropinocytosis drives lipid uptake and atherosclerotic plaque formation in mice and human arteries, highlighting a potential therapeutic target.
Accumulation of lipid-laden foam cells in the arterial wall plays a central role in atherosclerotic lesion development, plaque progression, and late-stage complications of atherosclerosis. However, there are still fundamental gaps in our knowledge of the underlying mechanisms leading to foam cell formation in atherosclerotic arteries. Here, we investigated the role of receptor-independent macropinocytosis in arterial lipid accumulation and pathogenesis of atherosclerosis. Genetic inhibition of fluid-phase macropinocytosis in myeloid cells ( LysMCre + Nhe1 fl/fl ) and repurposing of a Food and Drug Administration (FDA)–approved drug that inhibits macrophage macropinocytosis substantially decreased atherosclerotic lesion development in low-density lipoprotein (LDL) receptor–deficient and Apoe −/− mice. Stimulation of macropinocytosis using genetic ( H-RAS G12V ) and physiologically relevant approaches promoted internalization of unmodified native (nLDL) and modified [e.g., acetylated (ac) and oxidized (ox) LDL] lipoproteins in both wild-type and scavenger receptor (SR) knockout ( Cd36 −/− / Sra −/− ) macrophages. Pharmacological inhibition of macropinocytosis in hypercholesterolemic wild-type and Cd36 −/− / Sra −/− mice identified an important role of macropinocytosis in LDL uptake by lesional macrophages and development of atherosclerosis. Furthermore, serial section high-resolution imaging, LDL immunolabeling, and three-dimensional (3D) reconstruction of subendothelial foam cells provide visual evidence of lipid macropinocytosis in both human and murine atherosclerotic arteries. Our findings complement the SR paradigm of atherosclerosis and identify a therapeutic strategy to counter the development of atherosclerosis and cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2022) studied Atherosclerosis. Genetic and pharmacological inhibition of fluid-phase macropinocytosis vs. Wild-type or untreated control mice and macrophages was evaluated on Atherosclerotic lesion development and arterial foam cell formation. Genetic and pharmacological inhibition of fluid-phase macropinocytosis substantially decreased macrophage LDL uptake and atherosclerotic lesion development in hypercholesterolemic mice.
Synapse has enriched 10 related papers. Consider them for comparative context: